Navigation Links
KINAXO Completes Financing Round to Enhance Biomarker Development

Martinsried, Germany, November 20,2009 / b3c newswire / -KINAXO Biotechnologies GmbH announces the completion of a financing round, gaining two new investors in the company, Leifina and Conmit Invest. At the same time KINAXO reports that Jrgen Schumacher has been elected as a new member of the companys advisory board.

KINAXO shareholders Axel Ullrich, Hellmut Kirchner, Manfred Ferber as well as the companys institutional investors Mountain Partners, BioM, High-Tech Grnderfonds, the Max-Planck Society and the KfW ERP Start-Fonds also participated in this financing round. KINAXO will use the funds to develop novel biomarkers that allow stratification of cancer patients receiving targeted therapies.

KINAXOs CEO and co-founder Andreas Jenne said: There is little doubt that biomarkers will be one of the major drivers of pharmaceutical research and development in the 21st Century. Biomarkers have the potential to improve R&D efficiency and clinical success rates, save public health costs, and gain pharmaceutical companies a valuable advantage over their competitors. Following this trend we will make significant investments over the next few years to expand our phosphoproteomics services PhosphoScout and develop a novel class of biomarkers that help improve cancer therapies.

Horst Domdey, CEO of BioM, commented: KINAXO is in the right place at the right time. Today, biomarkers are more and more in demand to improve treatment options. With its unique phosphoproteomics platform that goes way beyond existing technologies, KINAXO is very well positioned in this rapidly growing market. Moreover, KINAXOs recent partnerships with Bayer and Roche underpin the industrys readiness to implement novel technologies turning personalized medicine into reality.

About KINAXO Biotechnologies GmbH
KINAXO is a privately-held biotechnology company based in Munich/Martinsried, Germany. KINAXO offers a unique technology tool box for drug mode-of-action analysis, cellular target profiling, target deconvolution, drug repositioning and biomarker identification. KINAXO maintains several collaborations with leading pharmaceutical companies, such as Bayer, Roche, Boehringer Ingelheim and Johnson & Johnson.

About KINAXOs PhosphoScout service
PhosphoScout is a quantitative phosphoproteomics service developed to investigate cellular signal transduction pathways and their response to drug treatment. It allows annotation and quantification of regulated phosphorylation sites in living cells, animal models and patient samples. Using state-of-the-art quantitative mass spectrometry up to 15,000 phosphorylation changes can be monitored in a single experiment, allowing system-wide modeling of cellular signaling events. Unlike immunoassays, PhosphoScout does not require antibodies for detection and thus enables unbiased phosphoproteome analyses across signaling pathways on a global scale.

About Leifina GmbH
Leifina is a diversified investment holding company managed by its founder Dr. Kurt Schwarz who held positions at Harvard Medical School, the Massachusetts General Hospital and Merck Sharp & Dohme. From 1990 to 2006 he was a member of the supervisory board of Schwarz Pharma. As a prominent private investor Schwarz is engaged in various biotechnology companies and private equity funds.

About Conmit Invest GmbH
Conmit invests in companies with exceptional prospects and outstanding management. Managing founder Hans-Milo Halhuber played a leading role in developing the German health care service market. From 1999 to 2009 Halhuber was Chairman of CURANUM, which under his leadership became Germanys biggest listed health care service company. As a serial entrepreneur Halhuber is actively involved in more than 20 companies.

About Dr. Jrgen Schumacher
Jrgen Schumacher is an internationally recognized German entrepreneur. He is a co-founder of Qiagen and principal founder of NewLab Bioquality, which he sold to Charles River Laboratories International in 2008. Besides being involved in several industry associations and other organizations, Schumacher is an experienced business angel who holds management and board positions in a number of biotechnology companies.

Dr. Andreas Jenne, CEO KINAXO Biotechnologies GmbH
Am Klopferspitz 19a, 82152 Martinsried, Germany

Phone: +49 89 46133630

b3c newswire

Related biology news :

1. KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex
2. KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue
3. KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
4. SyntheMed Completes $2.8 Million Equity Financing
5. Labwire Completes Its First Acquisition
6. bioMETRX, Inc. Completes Sequiam Asset Purchase
7. bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC
8. L-1 Identity Solutions Completes Acquisition of the ID Systems Business from Digimarc Corporation
9. DOE Joint Genome Institute completes soybean genome
10. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
11. Lockheed Martin Team Completes Key Design Milestone on Federal Bureau of Investigations Next Generation Identification Program
Post Your Comments:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... , June 2, 2016 Perimeter ... Platforms, Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... market will generate revenues of $17.98 billion in 2016. ... DVTEL Inc, a leader in software and hardware technologies ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Alex,s Lemonade Stand Foundation (ALSF), a leading national ... a state-of-the-art bioinformatics lab, using ,big data, to advance ... as Liz Scott , co-executive director of ALSF ... in Washington, D.C. , hosted by ... advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... , June 27, 2016  Sequenom, Inc. (NASDAQ: ... to enabling healthier lives through the development of innovative ... of the United States denied ... that the claims of Sequenom,s U.S. Patent No. 6,258,540 ... eligibility criteria established by the Supreme Court,s Mayo Collaborative ...
Breaking Biology Technology: